1-20 of 9451
brachial plexus neuritis
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Long-term treatment of venous thromboembolism

Clinical Trials & Observations
Clive Kearon, Susan R. Kahn
Journal: Blood
Blood (2020) 135 (5): 317–325.
https://doi.org/10.1182/blood.2019002364
Published: 2020
Journal Articles

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Saad Z. Usmani, MDMBBS, Hang Quach, MD, María-Victoria Mateos, Ola Landgren, MD PhD, Xavier Leleu, MD PhD, David S. Siegel, Katja Weisel, Hui Yang, Zandra K. Klippel, MD, Anita Zahlten-Kumeli, Meletios A. Dimopoulos, MD
Journal: Blood
Blood (2019) 134 (Supplement_2): LBA-6.
https://doi.org/10.1182/blood-2019-132629
Published: 2019
Journal Articles

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Andrew H. Wei, MBBS, FRACP, FRCPA, PhD, Hartmut Döhner, MD, Christopher Pocock, MBBS, Pau Montesinos, MD PhD, Boris Afanasyev, MD DSci, Hervé Dombret, MD, Farhad Ravandi, MD, Hamid Sayar, MD MSc, Jun Ho Jang, MD PhD, Kimmo Porkka, MD, Dominik Selleslag, MD, Irwindeep Sandhu, MD, Mehmet Turgut, MD, Valentina Giai, MD, Yishai Ofran, MD, Merih Kizil Cakar, MD, Aida Botelho de Sousa, MD, Justyna Rybka, MD PhD, Chiara Frairia, MD, Lorenza Borin, MD, Germana Beltrami, MD, Jaroslav Cermak, MD PhD, Gert J. Ossenkoppele, MD PhD, Ignazia La Torre, MD, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, CL Beach, PharmD, Gail J. Roboz, MD
Journal: Blood
Blood (2019) 134 (Supplement_2): LBA-3.
https://doi.org/10.1182/blood-2019-132405
Published: 2019
Journal Articles

Autologous Transplant Recipients Have a Healthier Gut Microbiota at Baseline and Faster Recovery from Microbiome Injury Compared to Allogeneic Transplant Recipients

Rajat Bansal, MD, Heekuk Park, Cristian Taborda, Christian Gordillo, BS, Markus Y. Mapara, MD PhD, Amer Assal, MD, Anne-Catrin Uhlemann, MD, Ran Reshef, MDMSc
Journal: Blood
Blood (2019) 134 (Supplement_1): 4491.
https://doi.org/10.1182/blood-2019-129304
Published: 2019
Journal Articles

Prevention and Management of Tumor Lysis Syndrome in Patients with CLL and Coexisting Conditions Treated with Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Results from the Randomized CLL14 Trial

Othman Al-Sawaf, MD, Anna-Maria Fink, MD, Sandra Robrecht, PhD, Arijit Sinha, PhD, Maneesh Tandon, MD, Barbara F. Eichhorst, MD, Kirsten Fischer, MD, Michael Hallek, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4315.
https://doi.org/10.1182/blood-2019-126570
Published: 2019
Journal Articles

Results from the Completed Dose-Escalation of the Hematological Arm of the Phase I Think Study Evaluating Multiple Infusions of NKG2D-Based CAR T-Cells As Standalone Therapy in Relapse/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

David A Sallman, MD, Jason B. Brayer, PhDMD, Xavier Poire, Violaine Havelange, Ahmad Awada, MD PhD, Philippe Lewalle, Kunle Odunsi, MD, Eunice S. Wang, MD, Caroline Lonez, PhD, Thomas Lequertier, Erik Alcantar-Orozco, MD, Nathalie Braun, Anne Flament, MD, Ine Moors, MD, Tessa Kerre
Journal: Blood
Blood (2019) 134 (Supplement_1): 3826.
https://doi.org/10.1182/blood-2019-128020
Published: 2019
Journal Articles

Evaluation of Biomarkers As Predictors of Blinatumomab Toxicity and Real-World Management of Blinatumomab Toxicity in B-Acute Lymphoblastic Leukemia Patients

Amber C. King, PharmD, BCOP, Jae H. Park, MD, Mark B. Geyer, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3887.
https://doi.org/10.1182/blood-2019-128506
Published: 2019
Journal Articles

Inotuzumab Ozogamicin Is an Effective Salvage Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia with High-Risk Molecular Features, Including TP53 Loss

Xiaochuan Yang, Amber C. King, PharmD, BCOP, Charlene C. Kabel, PharmD, Christopher J. Forlenza, MD, Jae H. Park, MD, Mark B. Geyer, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3888.
https://doi.org/10.1182/blood-2019-125165
Published: 2019
Journal Articles

A Retrospective Study on Inotuzumab Ozogamicin in Infants and Young Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Erica Brivio, MD, Raoull Hoogendijk, MSc, Christophe Chantrain, MD PhD, Fanny Rialland, MD, Audrey Contet, Sarah Elitzur, MD, Luciano Dalla-Pozza, MBBS FRACP, Krisztian Kallay, MD, Chi Kong Li, MBBS,MD, Motohiro Kato, MD PhD, Inna V Markova, Dr., Kjeld Schmiegelow, Professor MD DMSc., Nicole Bodmer, Rob Pieters, MDPhDMSc, Christian Michel Zwaan, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3890.
https://doi.org/10.1182/blood-2019-126472
Published: 2019
Journal Articles

High Risk Genomic Alterations Identified at the Time of Diagnosis Are Strongly Associated with MRD and Subsequent Poor Outcomes in AYA ALL Patients Treated on a Pediatric Inspired Chemotherapy Regimen

David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Matthew Greenwood, MBBS, FRACP, FRCPA, Jacqueline Rhen, BSc MSc MD, Susan L Heatley, PhD MD, Barbara McClure, BSc (Hons) PhD, Laura N Eadie, BSc (Hons) PhD, Jimmy Breen, BSc (Hons) PhD, Caitlin Schutz Schutz, BSc (Hons), Toby N Trahair, MBBS FRACP PhD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS, Luciano Dalla-Pozza, MBBS FRACP, Rosemary Sutton, BSc MSc PhD, Kenneth F Bradstock, BSc(MD, MBBS, PhD FRACP, FRCPA, Michael Philip Osborn, MB, BS, Deborah L. White, PhD FFSc (RCPA)
Journal: Blood
Blood (2019) 134 (Supplement_1): 3949.
https://doi.org/10.1182/blood-2019-127788
Published: 2019
Journal Articles

Early Follicular Lymphoma Progression in Patients Treated with Frontline Immunochemotherapy with/without Rituximab Maintenance: Clinically Meaningful Even in Chemosensitive Individuals

Vit K Prochazka, MD prof, David Belada, MD PhD, Andrea Janikova, MD PhD Assoc Prof, Katerina Benesova, MD PhD, Heidi Mocikova, MD PhD, Juraj Duras, MD, Robert Pytlik, MD PhD, Jan Pirnos, MD, Alice Sýkorová, MD PhD, Vit Campr, MD PhD, Jozef Michalka, MD, Kateřina Kopečková, MD PhD, Jitka Dlouha, Tomas Papajik, MD prof, Marek Trneny, MD prof
Journal: Blood
Blood (2019) 134 (Supplement_1): 3983.
https://doi.org/10.1182/blood-2019-129756
Published: 2019
Journal Articles

Elevated Serum Soluble Interleukin-2 Receptor Level Is a Useful Prognostic Factor for Disease-Specific Overall Survival in Patients with Newly Diagnosed Follicular Lymphoma before Initiation of Treatment

Kenji Nozaki, MD, Hiroyuki Sugahara, MD PhD, Shuji Ueda, MD PhD, Jun Ishikawa, MD PhD, Shigeo Fuji, MD PhD, Hiroaki Masaie, MD PhD, Yuma Tada, MD, Makiko Suga, MD, Kazuhito Tsutsumi, MD, Kumi Shibata, MD, Shuhei Kida, MD, Takahiro Karasuno, MD PhD, Hiroshi Sata, MD PhD, Masato Yasumi, MD PhD, Masato Iida, MD PhD, Hideki Mitsui, MD PhD, Tsuyoshi Kamae, MD PhD, Norimitsu Saito, MD PhD, Hiraku Murakami, MD, Yasuhiro Moriyama, MD PhD, Manabu Kawakami, MD PhD, Ruri Kato, MD PhD, Yoshiki Nakae, MD PhD, Toru Kida, MD, Satoru Kosugi, MD PhD, Hirohiko Shibayama, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3985.
https://doi.org/10.1182/blood-2019-126399
Published: 2019
Journal Articles

Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia

Hannah Asghari, MD, Dasom Lee, MD, Yehuda E. Deutsch, MD, Onyee Chan, MD, Najla Al Ali, M.Sc, Stephanie Boisclair, MD, Constance Terrell, PharmD, BCOP, Eric Padron, MD, Andrew T Kuykendall, MD, Alan F. List, MD, Hugo F. Fernandez, MD, Jeffrey E. Lancet, MD, David A Sallman, MD, Rami S. Komrokji, MD, Kendra L. Sweet, MD, Chetasi Talati, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3895.
https://doi.org/10.1182/blood-2019-130379
Published: 2019
Journal Articles

R-BAC Maintains High Response Rate in Mantle Cell Lymphoma Following Relapse on BTK Inhibitor Therapy

Rory McCulloch, FRCPath, MRCP, MBBS, Carlo Visco, Rebecca Frewin, Neil Phillips, Toby A. Eyre, David Tucker, MD, Francesca M. Quaglia, Annabel McMillan, Jonathan Lambert, Nicola Crosbie, Simon Rule
Journal: Blood
Blood (2019) 134 (Supplement_1): 3989.
https://doi.org/10.1182/blood-2019-129829
Published: 2019
Journal Articles

Population Pharmacokinetics and Novel Exposure-Response Analyses to Inform Optimal Biologic Dose Selection for CD20-TCB, a T-Cell-Engaging Bispecific Antibody, in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Nassim Djebli, PhD PharmD, Felix Jaminion, MSc, Johann Laurent, MSc, Francois Mercier, PhD, Nicole A Kratochwil, PhD, Ann-Marie E Bröske, PhD, Natalie Dimier, PhD, Cristiano Ferlini, MD, Tom Moore, MBChB, Martin Weisser, MD, Peter N Morcos, PharmD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3799.
https://doi.org/10.1182/blood-2019-123712
Published: 2019
Journal Articles

A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive Induction Therapy

William B. Donnellan, MD, Ehab L. Atallah, MD, Adam S. Asch, MD, Manish R. Patel, MD, Jay Yang, MD, Alireza Eghtedar, MD, Gautam M. Borthakur, MD, Julie Charlton, PhD, Alexander MacDonald, MSc-PhD, Anna Korzeniowska, MD, Elizabeth Sainsbury, BSc, Donald K. Strickland, MD, Suzanne Jones, PharmD, Philip Overend, MSc, Carrie A. Adelman, PhD, Giulia Fabbri, MD PhD, Jon Travers, PhD, Simon Smith, PhD, J. Elizabeth Pease, PhD, Jan Cosaert, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3919.
https://doi.org/10.1182/blood-2019-130635
Published: 2019
Journal Articles

First-in-Human Study of Abbv-621, a TRAIL Receptor Agonist Fusion Protein, in Patients (Pts) with Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML) and Diffuse Large B-Cell Lymphoma (DLBCL)

Maja J.A. de Jonge, MD, Benedito A. Carneiro, MD, Lot Devriese, MD PhD, Toshihiko Doi, MD PhD, Sudhir Penugonda, MD MPH, Adam M. Petrich, MD, Silpa Nuthalapati, PhD, Monica Motwani, PhD, Dimple A. Modi, PhD, Yu-Wei Chang, PhD, Emiliano Calvo, MD PhD, Victor Moreno, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3924.
https://doi.org/10.1182/blood-2019-129783
Published: 2019
Journal Articles

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse

Koji Sasaki, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Nicholas J. Short, MD, Partow Kebriaei, MD, Xuelin Huang, PhD, Michael E. Rytting, MD, Nitin Jain, MD, Marina Y Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Richard E. Champlin, MD, Tapan M. Kadia, MD, Jorge E. Cortes, MD, Zeev E. Estrov, MD, Koichi Takahashi, MD, Christopher Loiselle, BS, Corabelle Encarnacion, RDC, Meagan Rostykus, RN, Rita Khouri, Patrice Nasnas, MD, Jovitta Jacob, RN, Monica Kwari, BSN, Rebecca Garris, MSc, Elias Jabbour, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3806.
https://doi.org/10.1182/blood-2019-129018
Published: 2019
Journal Articles

Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≤ 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial

Michael L. Wang, MD, Preetesh Jain, MBBS,MDDM,PhD, Hun Ju Lee, MD, F. B. Hagemeister, MD, Felipe Samaniego, MD, Jason R. Westin, MD, Loretta J. Nastoupil, MD MSc, Wendy Chen, Krystle Nomie, PhD, Shaojun Zhang, PhD, Omar Moghrabi, Shuangtao Zhao, PhD, Rashmi Kanagal-Shamanna, MD, Chi Young Ok, MD, Onyeka Oriabure, Graciela M. Nogueras González, MPH, Dayoung Jung, Lucy Navsaria, MB BCh BAO, Ann Uy, Archie Pedersen, Liang Zhang, MD PhD, Changying Jiang, PhD, Feng Lei, MS, Yixin Yao, PhD, Guofang Xu, MD, Nicolaus Wagner-Bartak, MD, Selvi Thirumurthi, David Santos, Guilin Tang, MD, Keyur Patel, MD PhD, C. Cameron Yin, MD PhD, Michelle Avellaneda, Maria Badillo, Luis Fayad, MD, Sattva S Neelapu, MD, Nathan H. Fowler, MD, Jorge Enrique Romaguera, MD, Linghua Wang, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3987.
https://doi.org/10.1182/blood-2019-126044
Published: 2019
Journal Articles

Frontline Treatment with Ibrutinib with Rituximab (IR) Combination Is Highly Effective in Elderly (≥65 years) Patients with Mantle Cell Lymphoma (MCL) - Results from a Phase II Trial

Preetesh Jain, MBBS,MDDM,PhD, Hun Ju Lee, MD, Raphael Eric Steiner, MD, F. B. Hagemeister, MD, Felipe Samaniego, MD, Jason R. Westin, MD, Loretta J. Nastoupil, MD MSc, Sairah Ahmed, MD, Swaminathan P. Iyer, MD, Jorge Enrique Romaguera, MD, Shuangtao Zhao, PhD, Krystle Nomie, PhD, Chi Young Ok, MD, Rashmi Kanagal-Shamanna, MD, Onyeka Oriabure, Guofang Xu, MD, Liang Zhang, MD PhD, Changying Jiang, PhD, Dayoung Jung, Lucy Navsaria, MB BCh BAO, Wendy Chen, Omar Moghrabi, Tayyaba Nizam, Chloe Marie McClain, Maria Badillo, Selvi Thirumurthi, David Santos, Guilin Tang, MD, Keyur Patel, MD PhD, Sattva S Neelapu, MD, Linghua Wang, PhD, Nathan H. Fowler, MD, Michael L. Wang, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3988.
https://doi.org/10.1182/blood-2019-125800
Published: 2019